The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Oncogenic mutations of ALK kinase in neuroblastoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Self-citationFusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,409
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan-Smith, E., Dalton, J. D., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,801
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Nannya, Y., Sanada, M., Nakazaki, K., Hosoya, N., Wang, L., Hangaishi, A., Kurokawa, M., Chiba, S., Bailey, D. K., Kennedy, G. C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0465 · Cited by 639
Self-citationChromosome 1p and 11q Deletions and Outcome in Neuroblastoma
Attiyeh, E. F., London, W. B., Mossé, Y. P., Wang, Q., Winter, C., Khazi, D., McGrady, P. W., Seeger, R. C., Look, A. T., Shimada, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052399 · Cited by 580
Large-scale genotyping of complex DNA
Kennedy, G. C., Matsuzaki, H., Dong, S., Liu, W.-M., Huang, J., Liu, G., Su, X., Cao, M., Chen, W., Zhang, J., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt869 · Cited by 572
Cited by
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Recent Advances in Neuroblastoma
Maris, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0804577 · Cited by 1,983
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M., Solomon, B. J., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,309
The genetic landscape of high-risk neuroblastoma
Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., Carter, S. L., Cibulskis, K., Hanna, M., Kiezun, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2529 · Cited by 1,186
Advances in understanding cancer genomes through second-generation sequencing
Meyerson, M., Gabriel, S., & Getz, G. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2841 · Cited by 1,116
Doebele, R. C., Pilling, A. B., Aisner, D. L., Kutateladze, T. G., Le, A. T., Weickhardt, A. J., Kondo, K. L., Linderman, D. J., Heasley, L. E., Franklin, W. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2906 · Cited by 1,063
Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 932
Shaw, A. T., Yeap, B. Y., Solomon, B. J., Riely, G. J., Gainor, J., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S.-H. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 899
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
Molenaar, J. J., Koster, J., Zwijnenburg, D. A., van Sluis, P., Valentijn, L. J., van der Ploeg, I., Hamdi, M., van Nes, J., Westerman, B. A., van Arkel, J., et al. (2012) · Nature · doi:10.1038/nature10910 · Cited by 870
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J., Goel, N., Aronson, A. B., Li, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0349 · Cited by 868
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
Cheung, N.-K. V., & Dyer, M. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3526 · Cited by 801
Takeuchi, K., Choi, Y. L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., Takada, S., Ueno, T., Yamashita, Y., Satoh, Y., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3248 · Cited by 717
Self-citationMossé, Y. P., Lim, M. S., Voss, S. D., Wilner, K., Ruffner, K., Laliberte, J., Rolland, D., Balis, F. M., Maris, J. M., Weigel, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70095-0 · Cited by 712
Rodig, S. J., Mino-Kenudson, M., Dacic, S., Yeap, B. Y., Shaw, A., Barletta, J. A., Stubbs, H., Law, K., Lindeman, N., Mark, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0802 · Cited by 678
Huang, M., & Weiss, W. A. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014415 · Cited by 647
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Hallberg, B., & Palmer, R. H. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3580 · Cited by 645
Cancer genomics: from discovery science to personalized medicine
Chin, L., Andersen, J. N., & Futreal, P. A. (2011) · Nature Medicine · doi:10.1038/nm.2323 · Cited by 644
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0418 · Cited by 637
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Sakamoto, H., Tsukaguchi, T., Hiroshima, S., Kodama, T., Kobayashi, T., Fukami, T. A., Oikawa, N., Tsukuda, T., Ishii, N., & Aoki, Y. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.004 · Cited by 636
Neuroblastoma: Biology, Prognosis, and Treatment
Park, J. R., Eggert, A., & Caron, H. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.11.011 · Cited by 620
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
Johnson, T. W., Richardson, P. F., Bailey, S., Brooun, A., Burke, B. J., Collins, M. R., Cui, J. J., Deal, J. G., Deng, Y.-L., Dinh, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500261q · Cited by 594
Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries
Boeva, V., Louis-Brennetot, C., Peltier, A., Durand, S., Pierre-Eugène, C., Raynal, V., Etchevers, H. C., Thomas, S., Lermine, A., Daudigeos-Dubus, E., et al. (2017) · Nature Genetics · doi:10.1038/ng.3921 · Cited by 494
Kinase mutations in human disease: interpreting genotype–phenotype relationships
Lahiry, P., Torkamani, A., Schork, N. J., & Hegele, R. A. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2707 · Cited by 420
Anaplastic lymphoma kinase: signalling in development and disease
Palmer, R. H., Vernersson, E., Grabbe, C., & Hallberg, B. (2009) · Biochemical Journal · doi:10.1042/bj20090387 · Cited by 423
Sausen, M., Leary, R. J., Jones, S., Wu, J., Reynolds, C. P., Liu, X., Blackford, A., Parmigiani, G., Diaz, L. A., Papadopoulos, N., et al. (2013) · Nature Genetics · doi:10.1038/ng.2493 · Cited by 414
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms
Sanada, M., Suzuki, T., Shih, L.-Y., Otsu, M., Kato, M., Yamazaki, S., Tamura, A., Honda, H., Sakata-Yanagimoto, M., Kumano, K., et al. (2009) · Nature · doi:10.1038/nature08240 · Cited by 402
Self-citationOverview and recent advances in the treatment of neuroblastoma
Whittle, S. B., Smith, V., Doherty, E., Zhao, S., McCarty, S., & Zage, P. E. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1285230 · Cited by 394
Irwin, M. S., & Park, J. R. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.015 · Cited by 392
Bresler, S. C., Weiser, D. A., Huwe, P. J., Park, J. H., Krytska, K., Ryles, H., Laudenslager, M., Rappaport, E. F., Wood, A. C., McGrady, P. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.019 · Cited by 388
Walker, A. J., Majzner, R. G., Zhang, L., Wanhainen, K., Long, A. H., Nguyen, S. M., Lopomo, P., Vigny, M., Fry, T. J., Orentas, R. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.008 · Cited by 383
Molecular targeting therapies for neuroblastoma: Progress and challenges
Zafar, A., Wang, W., Liu, G., Wang, X., Xian, W., McKeon, F., Foster, J., Zhou, J., & Zhang, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21750 · Cited by 380
The role of the ALK receptor in cancer biology
Hallberg, B., & Palmer, R. H. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw301 · Cited by 377
Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis
Zhu, S., Lee, J.-S., Guo, F., Shin, J., Perez-Atayde, A. R., Kutok, J. L., Rodig, S. J., Neuberg, D. S., Helman, D., Feng, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.010 · Cited by 365
Pediatric low-grade glioma in the era of molecular diagnostics
Ryall, S., Tabori, U., & Hawkins, C. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00902-z · Cited by 351
Solomon, B., Varella-Garcia, M., & Camidge, D. R. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c4dedb · Cited by 343
Pandey, G. K., Mitra, S., Subhash, S., Hertwig, F., Kanduri, M., Mishra, K., Fransson, S., Ganeshram, A., Mondal, T., Bandaru, S., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.014 · Cited by 343
Functional Enhancers Shape Extrachromosomal Oncogene Amplifications
Morton, A. R., Dogan-Artun, N., Faber, Z. J., MacLeod, G., Bartels, C. F., Piazza, M. S., Allan, K. C., Mack, S. C., Wang, X., Gimple, R. C., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.039 · Cited by 343
Making sense of cancer genomic data
Chin, L., Hahn, W. C., Getz, G., & Meyerson, M. (2011) · Genes & Development · doi:10.1101/gad.2017311 · Cited by 336
Sasaki, T., Okuda, K., Zheng, W., Butrynski, J., Capelletti, M., Wang, L., Gray, N. S., Wilner, K., Christensen, J. G., Demetri, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2956 · Cited by 335
Self-citationYamagishi, M., Nakano, K., Miyake, A., Yamochi, T., Kagami, Y., Tsutsumi, A., Matsuda, Y., Sato-Otsubo, A., Muto, S., Utsunomiya, A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.015 · Cited by 329
Self-citationThe ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
Berry, T., Luther, W., Bhatnagar, N., Jamin, Y., Poon, E., Sanda, T., Pei, D., Sharma, B., Vetharoy, W. R., Hallsworth, A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.001 · Cited by 326
VI, J. G. T., Cheuk, A. T., Tsang, P. S., Chung, J.-Y., Song, Y. K., Desai, K., Yu, Y., Chen, Q.-R., Shah, K., Youngblood, V., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39703 · Cited by 321
EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer
Horn, L., & Pao, W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6661 · Cited by 319
Integrative genomics identifies LMO1 as a neuroblastoma oncogene
Wang, K., Diskin, S. J., Zhang, H., Attiyeh, E. F., Winter, C., Hou, C., Schnepp, R. W., Diamond, M., Bosse, K., Mayes, P. A., et al. (2011) · Nature · doi:10.1038/nature09609 · Cited by 310
Neuroblastoma: clinical and biological approach to risk stratification and treatment
Tolbert, V. P., & Matthay, K. K. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2821-2 · Cited by 304
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Jänne, P. A., Gray, N., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 303
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Roskoski, R. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.007 · Cited by 303
Implementing personalized cancer genomics in clinical trials
Simon, R., & Roychowdhury, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3979 · Cited by 301
Menichincheri, M., Ardini, E., Magnaghi, P., Avanzi, N., Banfi, P., Bossi, R., Buffa, L., Canevari, G., Ceriani, L., Colombo, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00064 · Cited by 299
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297
Zhang, X., Zhang, S., Yang, X., Yang, J., Zhou, Q., Yin, L., An, S., Lin, J., Chen, S., Xie, Z., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-188 · Cited by 296
The prenatal origins of cancer
Marshall, G. M., Carter, D. R., Cheung, B. B., Liu, T., Mateos, M. K., Meyerowitz, J. G., & Weiss, W. A. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3679 · Cited by 281
Mechanisms of neuroblastoma regression
Brodeur, G. M., & Bagatell, R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.168 · Cited by 284
De Brouwer, S., De Preter, K., Kumps, C., Zabrocki, P., Porcu, M., Westerhout, E. M., Lakeman, A., Vandesompele, J., Hoebeeck, J., Van Maerken, T., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2660 · Cited by 279
Self-citationUpdates in Diagnosis, Management, and Treatment of Neuroblastoma
Swift, C. C., Eklund, M. J., Kraveka, J. M., & Alazraki, A. L. (2018) · RadioGraphics · doi:10.1148/rg.2018170132 · Cited by 279
The molecular pathology of cancer
Harris, T. J. R., & McCormick, F. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.41 · Cited by 276
Golding, B., Luu, A., Jones, R., & Viloria-Petit, A. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0810-4 · Cited by 273
Family-based designs for genome-wide association studies
Ott, J., Kamatani, Y., & Lathrop, M. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2989 · Cited by 271
Kelly, L. M., Barila, G., Liu, P., Evdokimova, V. N., Trivedi, S., Panebianco, F., Gandhi, M., Carty, S. E., Hodak, S. P., Luo, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321937111 · Cited by 271
Yi, E. S., Boland, J. M., Maleszewski, J. J., Roden, A. C., Oliveira, A. M., Aubry, M.-C., Erickson-Johnson, M. R., Caron, B. L., Li, Y., Tang, H., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318209edb9 · Cited by 263
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Katayama, R., Lovly, C. M., & Shaw, A. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2791 · Cited by 257
Anaplastic Lymphoma Kinase Spares Organ Growth during Nutrient Restriction in Drosophila
Cheng, L. Y., Bailey, A. P., Leevers, S. J., Ragan, T. J., Driscoll, P. C., & Gould, A. P. (2011) · Cell · doi:10.1016/j.cell.2011.06.040 · Cited by 252
Treating ALK-positive lung cancer—early successes and future challenges
Camidge, D. R., & Doebele, R. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.43 · Cited by 236
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
Zhang, C., Han, X.-R., Yang, X., Jiang, B., Liu, J., Xiong, Y., & Jin, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.071 · Cited by 226
Commonality but Diversity in Cancer Gene Fusions
Rabbitts, T. H. (2009) · Cell · doi:10.1016/j.cell.2009.04.034 · Cited by 73
Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival
Thole, T. M., Lodrini, M., Fabian, J., Wuenschel, J., Pfeil, S., Hielscher, T., Kopp-Schneider, A., Heinicke, U., Fulda, S., Witt, O., et al. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.49 · Cited by 67
Zebrafish Leucocyte tyrosine kinase controls iridophore establishment, proliferation and survival
Fadeev, A., Krauss, J., Singh, A. P., & Nüsslein‐Volhard, C. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12454 · Cited by 58
Berko, E. R., Witek, G. M., Matkar, S., Petrova, Z. O., Wu, M. A., Smith, C. M., Daniels, A., Kalna, J., Kennedy, A., Gostuski, I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38195-0 · Cited by 53
Wang, H. Q., Halilovic, E., Li, X., Liang, J., Cao, Y., Rakiec, D. P., Ruddy, D. A., Jeay, S., Wuerthner, J. U., Timple, N., et al. (2017) · eLife · doi:10.7554/elife.17137 · Cited by 45
A Simple, Highly Visual in Vivo Screen for Anaplastic Lymphoma Kinase Inhibitors
Rodrigues, F. S. L. M., Yang, X., Nikaido, M., Liu, Q., & Kelsh, R. N. (2012) · ACS Chemical Biology · doi:10.1021/cb300361a · Cited by 15
Ek, T., Ibrahim, R. R., Vogt, H., Georgantzi, K., Träger, C., Gaarder, J., Djos, A., Rahmqvist, I., Mellström, E., Pujol-Calderón, F., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0338 · Cited by 15
Metadata
- Authors
- Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., Nakagawara, A., Hayashi, Y., Mano, H., & Ogawa, S.
- Venue
- Nature
- Published
- 2008-10
- Volume
- 455
- Issue
- 7215
- Pages
- 971-974
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2035282066
- Cited by
- 916
- References
- 20
- FWCI
- 37.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.